Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million

Core Viewpoint - Vivoryon Therapeutics N.V. has successfully completed a private placement, raising EUR 5.1 million to support the development of its lead candidate, varoglutamstat, for chronic kidney disease [2][3][6]. Financial Summary - The private placement involved the issuance of 3,380,500 new ordinary shares at an offering price of EUR 1.50 per share, resulting in gross proceeds of EUR 5.1 million [4]. - The new shares represent 12.9% of Vivoryon's existing issued share capital, increasing the total number of shares outstanding to 29,614,337 and the share capital to EUR 296,143.37 [4][8]. Use of Proceeds - The funds raised will be utilized for the ongoing clinical development of varoglutamstat, securing a strategic partnership, and potentially additional funding for a planned Phase 2 study in diabetic kidney disease [6][8]. - The company anticipates that the existing cash, including the proceeds from this placement, will be sufficient to fund operations into Q3 2026 [7][8]. Market Position and Strategy - Vivoryon is focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly targeting kidney diseases [3][9]. - The successful financing reflects investor confidence in the company's strategy and its program for varoglutamstat [6].